Passage Bio Stock Current Valuation
| PASG Stock | USD 0.51 0.03 5.56% |
Valuation analysis of Passage Bio helps investors to measure Passage Bio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. The current Enterprise Value Over EBITDA is estimated to decrease to -0.64. The current Enterprise Value Multiple is estimated to decrease to -0.64. Fundamental drivers impacting Passage Bio's valuation include:
Price Book 0.4553 | Enterprise Value -25.9 M | Enterprise Value Ebitda 0.8725 |
Overvalued
Today
Please note that Passage Bio's price fluctuation is out of control at this time. Calculation of the real value of Passage Bio is based on 3 months time horizon. Increasing Passage Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Passage stock is determined by what a typical buyer is willing to pay for full or partial control of Passage Bio. Since Passage Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Passage Stock. However, Passage Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.51 | Real 0.5 | Target 6.67 | Hype 0.54 | Naive 0.45 |
The real value of Passage Stock, also known as its intrinsic value, is the underlying worth of Passage Bio Company, which is reflected in its stock price. It is based on Passage Bio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Passage Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Passage Bio helps investors to forecast how Passage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Passage Bio more accurately as focusing exclusively on Passage Bio's fundamentals will not take into account other important factors: Passage Bio Company Current Valuation Analysis
Passage Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Passage Bio Current Valuation | (25.9 M) |
Most of Passage Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Passage Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Passage Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Passage Bio is extremely important. It helps to project a fair market value of Passage Stock properly, considering its historical fundamentals such as Current Valuation. Since Passage Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Passage Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Passage Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Passage Current Valuation Historical Pattern
Today, most investors in Passage Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Passage Bio's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Passage Bio current valuation as a starting point in their analysis.
Passage Bio Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Passage Bio has a Current Valuation of (25.9 Million). This is 100.18% lower than that of the Biotechnology sector and 100.56% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.16% higher than that of the company.
Passage Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Passage Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Passage Bio could also be used in its relative valuation, which is a method of valuing Passage Bio by comparing valuation metrics of similar companies.Passage Bio is currently under evaluation in current valuation category among its peers.
Passage Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | (25.9 M) | ||||
| Shares Outstanding | 61.77 M | ||||
| Shares Owned By Insiders | 0.49 % | ||||
| Shares Owned By Institutions | 59.68 % | ||||
| Number Of Shares Shorted | 1.64 M | ||||
| Price To Book | 0.46 X | ||||
| EBITDA | (98.34 M) | ||||
| Net Income | (102.06 M) | ||||
| Cash And Equivalents | 239.25 M | ||||
| Cash Per Share | 4.39 X | ||||
| Total Debt | 26.29 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 9.23 X | ||||
| Book Value Per Share | 2.02 X | ||||
| Cash Flow From Operations | (78.26 M) | ||||
| Short Ratio | 6.61 X | ||||
| Earnings Per Share | (1.17) X | ||||
| Target Price | 7.67 | ||||
| Number Of Employees | 58 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 33.11 M | ||||
| Total Asset | 150.54 M | ||||
| Retained Earnings | (594.47 M) | ||||
| Working Capital | 101.62 M | ||||
| Current Asset | 144.91 M | ||||
| Current Liabilities | 3.09 M | ||||
| Net Asset | 150.54 M |
About Passage Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Passage Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Passage Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Passage Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Passage Bio is a strong investment it is important to analyze Passage Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Passage Bio's future performance. For an informed investment choice regarding Passage Stock, refer to the following important reports:Check out Passage Bio Piotroski F Score and Passage Bio Altman Z Score analysis. For more detail on how to invest in Passage Stock please use our How to Invest in Passage Bio guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Passage Bio. If investors know Passage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Passage Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.34) | Return On Equity (0.64) |
The market value of Passage Bio is measured differently than its book value, which is the value of Passage that is recorded on the company's balance sheet. Investors also form their own opinion of Passage Bio's value that differs from its market value or its book value, called intrinsic value, which is Passage Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Passage Bio's market value can be influenced by many factors that don't directly affect Passage Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Passage Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Passage Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Passage Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.